Merck’s experimental oral cholesterol medication has passed another Phase 3 clinical trial, advancing toward regulatory approval and expanding treatment options in a class largely dominated by injectable therapies. This development reinforces Merck’s cholesterol portfolio strength and marks progress in oral lipid-lowering agent innovation. The trial outcome boosts expectations for commercial success in a market with significant unmet need for convenient cholesterol management.